Physiological notch signaling maintains bone homeostasis via RBPjk and Hey upstream of NFATc1

Xiaolin Tu
Washington University School of Medicine in St. Louis

Jianquan Chen
Washington University School of Medicine in St. Louis

Joohyun Lim
Washington University School of Medicine in St. Louis

Courtney M. Karner
Washington University School of Medicine in St. Louis

Seung-Yon Lee
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Part of the Medicine and Health Sciences Commons

Recommended Citation
Tu, Xiaolin; Chen, Jianquan; Lim, Joohyun; Karner, Courtney M.; Lee, Seung-Yon; Heisig, Julia; Wiese, Cornelia; Surendran, Kameswaran; Kopan, Raphael; Gessler, Manfred; and Long, Fanxin, "Physiological notch signaling maintains bone homeostasis via RBPjk and Hey upstream of NFATc1." PLoS Genetics. 8,3. 1-13. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/1020

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Physiological Notch Signaling Maintains Bone Homeostasis via RBPjk and Hey Upstream of NFATc1

Xiaolin Tu1*, Jianquan Chen1, Joohyun Lim1, Courtney M. Karner1, Seung-Yon Lee1, Julia Heisig2, Cornelia Wiese2, Kameswaran Surendran3, Raphael Kopan3, Manfred Gessler2, Fanxin Long1,3*

1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Developmental Biochemistry, Biocentre, University of Wuerzburg, Wuerzburg, Germany, 3 Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, United States of America

Abstract

Notch signaling between neighboring cells controls many cell fate decisions in metazoans both during embryogenesis and in postnatal life. Previously, we uncovered a critical role for physiological Notch signaling in suppressing osteoblast differentiation in vivo. However, the contribution of individual Notch receptors and the downstream signaling mechanism have not been elucidated. Here we report that removal of Notch2, but not Notch1, from the embryonic limb mesenchyme markedly increased trabecular bone mass in adolescent mice. Deletion of the transcription factor RBPjk, a mediator of all canonical Notch signaling, in the mesenchymal progenitors but not the more mature osteoblast-lineage cells, caused a dramatic high-bone-mass phenotype characterized by increased osteoblast numbers, diminished bone marrow mesenchymal progenitor pool, and rapid age-dependent bone loss. Moreover, mice deficient in Hey1 and HeyL, two target genes of Notch-RBPjk signaling, exhibited high bone mass. Interestingly, Hey1 bound to and suppressed the NFATc1 promoter, and RBPjk deletion increased NFATc1 expression in bone. Finally, pharmacological inhibition of NFAT alleviated the high-bone-mass phenotype caused by RBPjk deletion. Thus, Notch-RBPjk signaling functions in part through Hey1-mediated inhibition of NFATc1 to suppress osteoblastogenesis, contributing to bone homeostasis in vivo.

Introduction

Notch signaling mediates communication between neighboring cells to control cell fate decisions in all metazoans [1,2]. The mammalian genome encodes four Notch receptors (Notch1-4) and at least five ligands (Jagged1, 2 and Delta-like 1, 3, 4) [3]. In the canonical Notch pathway, binding of the ligands to the Notch receptors present on the neighboring cell surface triggers two successive intramembrane proteolytic cleavages of the receptors mediated by the γ-secretase complex and resulting in the release of the Notch intracellular domain (NICD) [4,5,6]. Upon its release from the plasma membrane, NICD translocates to the nucleus where it interacts with a transcription factor of the CSL family (RBPjk/CBF-1 in mammals) to activate transcription of target genes [7]. Among the best known targets of Notch/RBPjk signaling are the Hes/Hey family of basic helix-loop-helix (bHLH) transcription repressors [8]. However, the regulation of individual Hes/Hey proteins by Notch and their role in mediating Notch function are highly dependent on cell context. In addition to the canonical pathway, Notch has also been reported to signal through noncanonical, RBPjk-independent mechanisms, but the molecular nature of these mechanisms is not well understood [6,9,10,11].

Notch signaling has emerged as a critical regulator of the mammalian skeleton. Initial mouse genetic studies identified a role for Notch in axial skeletal patterning, as mice lacking either Delta-like 3 (Dll3) [12], presenilin 1 (PS1) [13,14], a catalytic subunit of the γ-secretase complex, or lunatic fringe, a glycosyltransferase that modifies Notch proteins [15], exhibited defects in the axial skeleton due to deficiency in somite segmentation and maintenance. In addition, mice lacking either Notch1 and 2 specifically in the limb bud ectoderm or Jagged2 globally displayed syndactyly [16,17]. Consistent with the mouse studies, human mutations in Dll3 [18] were found to cause spondylocostal dysostosis, whereas those in Notch2 [10] and Jagged1 [19,20] were responsible for Alagille syndrome.

More recent mouse genetic studies have expanded our view of Notch function in the osteoblast lineage. By genetically removing both catalytic subunits of the γ-secretase complex, PS1 and PS2, or both Notch1 and 2 in the embryonic limb mesenchyme, we have shown that Notch critically controls postnatal bone homeostasis: the Notch-deficient long bones exhibited excessive bone formation in adolescent mice with concomitant loss of bone marrow mesenchymal progenitors [21]. Consistent with the negative role of Notch in osteoblast differentiation, Zanotti et al reported that forced-expression of NICD in osteoblastic precursors reduced osteoblast numbers and caused osteopenia [22]. Conversely, forced-expression of NICD at a later stage of the osteoblast lineage led to sclerosis owing to excessive proliferation of the
Author Summary

Osteoporosis is a disease caused by disruption of the balance between bone formation and resorption resulting in a net loss of bone mass. Although anti-resorptive agents are the current mainstay of osteoporosis therapy, novel strategies to promote bone formation are critically needed for more effective prevention and treatment of the disease. Notch signaling, an evolutionally conserved mechanism among multi-cellular organisms, was recently shown to control bone formation and therefore represents a potential target pathway for novel bone-promoting therapeutics. In this study we elucidate the intracellular signaling mechanism through which Notch controls bone formation, providing a molecular framework that may guide future drug development.

immature osteoblasts, highlighting stage-specific functions of constitutive Notch activity in the osteoblast lineage [23,24]. The negative role of physiological Notch signaling in osteoblast differentiation uncovered in mice is congruent with the clinical findings that Notch1 haploinsufficiency causes ectopic osteoblast differentiation and calcification in the aortic valves [25,26], whereas Notch2 stabilizing mutations are responsible for the Hadju-Cheney syndrome, a disorder of severe and progressive bone loss [27,28]. However, the signaling cascade through which Notch inhibits osteoblastogenesis is not yet well understood.

Here we have genetically assessed the role of RBPjk and Hey proteins, known components of the Notch canonical pathway, in the regulation of osteoblastogenesis. Moreover, we have evaluated the role of NFAT in the high-bone-mass phenotype caused by RBPjk deficiency. The NFAT1 (nuclear factor of activated T cells) family of transcription factors (NFATc1-c4) [29] have been shown to play important roles in several skeletal cell types, including chondrocytes [30], osteoclasts [31] and osteoblasts [32,33]. Our results support a model wherein canonical Notch signaling suppresses osteoblastogenesis in part through inhibition of NFATc1 transcription, therefore integrating extracellular signals with transcription factors that control osteoblast differentiation.

Results

Notch2 plays a dominant role in suppressing bone formation

Previously, simultaneous removal of both Notch1 and 2 (PNN mice) from the embryonic limb mesenchyme with Prx1-Cre, which targets all of the early limb bud mesenchyme and a subset of the craniofacial mesenchyme [34], caused high bone mass due to increased osteoblast differentiation [21]. To discern the individual contributions of Notch1 versus 2 in the osteogenic progenitors, we employed the same Cre-loxP strategy to delete the two receptors separately. Western analyses confirmed that Notch1 or Notch2 was efficiently deleted in the limb mesenchyme of Prx1-Cre; Notch1<sup>fl/fl</sup> (PN1) or Prx1-Cre; Notch2<sup>fl/fl</sup> (PN2) mice, respectively (Figure 1A). As expected from our previous study of the PNN mice, PN1 and PN2 mice were viable without gross morphological anomalies. However, X-ray radiography of the limb bones at eight weeks of age revealed a marked increase in mineral content within the presumptive bone marrow cavity than the wild-type littermates (Figure 2C). μCT analysis of the proximal tibia confirmed a marked increase of bone mass in the PRBP mice (Figure 2C), as reflected in a 730%, 220% or 140% increase in BV/TV, trabecular number or trabecular thickness, respectively, coupled with a 70% decrease in trabecular spacing (Table 2). Consistent with the μCT data, both H&E and picrosirius red staining of the tibia detected excessive trabecular bone occluding much of the marrow cavity of the PRBP bones (Figure 2D, 2E). These analyses also revealed an abnormal elongation of the growth plate hypertrophic cartilage in the PRBP bones (Figure 3A, 3B). The dramatic increase in bone mass in the PRBP mice was very similar to that seen in the presenilin 1- and 2-deficient (PPS) animals, but more severe than the PNN phenotype, likely due to contributions from Notch3 and 4 in the PNN mice [21], indicating that Notch 1 performed a discernible role in the absence of Notch 2, even though deletion of Notch 1 alone did not cause an effect. Similar to the PNN mice, the high bone mass in PN2 mice was not due to decreased total osteoclast activities, as serum CTX levels, which reflect the amount of cleaved type I collagen by osteoclasts in the whole animal, did not differ significantly from the controls (Figure 1C). In addition, osteoclast number or osteoclast surface per bone perimeter did not change in either PN1 or PN2 mice (Figure 1D–1E). Therefore, physiological signaling from Notch 2, rather than Notch 1, plays a dominant role in suppressing bone formation.

RBPjk mediates Notch function in suppressing osteoblast differentiation

To test the hypothesis that Notch suppresses bone formation through the canonical pathway, we deleted RBPjk with Prx1-Cre from the embryonic limb mesenchyme. Western analyses confirmed that RBPjk was efficiently deleted in the tibia of the Prx1-Cre; RBPjk<sup>fl/fl</sup> (PRBP) mouse (Figure 2A). Moreover, Hey1 and Hey2, two Notch target genes previously identified in the PNN bones [21], were markedly reduced in the PRBP tibia (Figure 2B). The PRBP mice were born at mendelian ratio with no gross abnormalities. However, at eight weeks of age, X-ray radiography revealed that the PRBP mice contained much greater mineral content within the presumptive bone marrow cavity than the PNN bones [21] (Figure 1B), indicating that Notch 1 performed a discernible role in the absence of Notch 2, even though deletion of Notch 1 alone did not cause an effect. Similar to the PNN mice, the high bone mass in PN2 mice was not due to decreased total osteoclast activities, as serum CTX levels, which reflect the amount of cleaved type I collagen by osteoclasts in the whole animal, did not differ significantly from the controls (Figure 1C). In addition, osteoclast number or osteoclast surface per bone perimeter did not change in either PN1 or PN2 mice (Figure 1D–1E). Therefore, physiological signaling from Notch 2, rather than Notch 1, plays a dominant role in suppressing bone formation.
percentage of bone surface covered by osteoclasts (OC. S./B. S.) (Figure 3D). Thus, the PRBP mice possessed abundant, but apparently less functional osteoclasts within the metaphyseal trabecular bone. Real-time PCR experiments showed that the mRNA levels for both the osteoclastogenic signal Rankl and the anti-osteoclastogenic factor Opg were reduced in the PRBP bone, but the ratio of Rankl over Opg (Rankl/Opg) was 230% higher in the PRBP bone than the control (Figure 3E). Moreover, the mRNA level for M-CSF, a potent mitogen of osteoclast precursors, was 690% higher in the PRBP mice (Figure 3F). The higher level of M-CSF coupled with an increased ratio of Rankl/Opg could explain the supernumerary but dysfunctional osteoclasts populat-
ing the metaphyseal trabecular bone in the PRBP mice. Overall, the high bone mass in the PRBP mice was not caused by an overall decrease in bone resorption.

Having ruled out resorption deficiency as the main cause for the high bone mass in the PRBP mice, we next focused on bone formation parameters. Static histomorphometry of tibial sections from the eight-week-old PRBP mice revealed a marked increase in the number of cuboidal (active) osteoblasts, when normalized to either bone perimeter (60% increase) or trabecular bone area (400% increase) (Figure 4A). The number of flat (inactive) osteoblasts, when normalized to trabecular bone area, was also increased by 100% in the PRBP mice. Consistent with the increase in osteoblast number, real-time PCR experiments showed that a number of common osteoblast markers were upregulated in bone total RNA (Figure 4B). Dynamic histomorphometry showed that the mineral apposition rate (MAR), which measured osteoblast activity, did not

Table 2. Age-dependent bone loss in PRBP mice.

| Age  | Genotype | BV/TV  | Ratio over WT | p value | Tb.N*  | Ratio over WT | p value | Tb.Th*  | Ratio over WT | p value | Tb.Sp*  | Ratio over WT | p value |
|------|----------|--------|--------------|---------|--------|--------------|---------|--------|--------------|---------|--------|--------------|---------|
|      |          | % (±s.d.) |     |     |    | mm (±s.d.) |     | mm (±s.d.) |     | mm (±s.d.) |     |
| 8 weeks | PRBP | 47.217±11.535 | 8.3 | 0.003 | 5.683±0.980 | 3.2 | 0.002 | 0.1373±0.046 | 2.4 | 0.038 | 0.180±0.027 | 0.3 | 0.000 |
|        | WT     | 5.660±0.986   | 1.781±0.075 | 0.057±0.001 | 0.577±0.030 |
| 26 weeks | PRBP | 24.700±4.740 | 1.5 | 0.181 | 4.553±1.473 | 2.3 | 0.016 | 0.080±0.011 | 1.0 | 0.930 | 0.248±0.114 | 0.4 | 0.374 |
|        | WT     | 16.275±1.622   | 1.965±0.333 | 0.079±0.010 | 0.552±0.095 |

BV: bone volume; TV: total volume; Tb.N*: trabeculae number; Tb.Th*: trabeculae thickness; Tb.Sp*: trabeculae spacing; data derived from 100 of 16-μm slices immediately below growth plate. All analyses were performed with sex-matched littermates (1 male and 2 females for 8 weeks, 2 males and 2 females for 26 weeks). doi:10.1371/journal.pgen.1002577.t002
differ significantly between PRBP and the control littermates (Figure 4C). However, the percentage of double-labeled trabecular bone surface was increased by 230% in the PRBP mice, resulting in a significant increase in the bone formation rate (BFR) within the trabecular region (Figure 4C). Thus, the increase in bone mass in the PRBP mice was primarily due to a marked increase in osteoblast numbers.

To explore the mechanism responsible for the increase in osteoblast numbers, we assessed the status of apoptosis and proliferation of osteoblasts in PRBP versus wild-type bones. To this end, osteoblast protein extracts were prepared from the bone surface of the long bones, and subjected to Western analyses for activated caspase 3 and PCNA, markers for apoptosis and cell proliferation, respectively. These assays did not detect a significant difference in either protein between the genotypes (Figure 4D). Therefore, the increase in osteoblast numbers is unlikely to be caused by changes in apoptosis or proliferation, but rather due to enhanced differentiation from the progenitors.

RBPj deletion causes diminution of bone marrow mesenchymal progenitor pool and rapid age-dependent bone loss

Uncontrolled osteoblast differentiation may lead to loss of bone marrow mesenchymal progenitors and rapid age-dependent bone loss [21]. To test whether this is the case in the PRBP mice, we analyzed bone mass by X-ray (data not shown) and μCT at 26 weeks of age. Indeed, bone mass was drastically reduced in the PRBP mice at 26 weeks when compared with 8 weeks (Figure 5A). When quantified, the trabecular bone mass of the PRBP tibia was no longer significantly different from the wild type at 26 weeks, representing a drastic decline from a level 730% above normal at 8 weeks (Table 2). Similarly, both trabecular thickness and number were reduced to levels either equivalent or close to the wild type.

Bone resorption, as measured by serum CTX assays, was significantly higher in the PRBP mice over the control at 26 weeks, likely contributing to the rapid bone loss (Figure 5B).
Thus, similar to the PNN mice [21], the PRBP mice, despite their high bone mass when young, rapidly lost bone with age.

We next assessed the status of the mesenchymal progenitors in the bone marrow. To this end, bone marrow stromal cells (BMSC) isolated from PRBP versus wild type littermates were subjected to CFU-F (colony forming unit-fibroblast) assays. These assays were not feasible with adolescent PRBP mice due to the occlusion of the marrow cavity, and therefore performed only after six months of age. Remarkably, no type I CFU-Fs could be detected from the PRBP bone marrow at either 26 weeks (data not shown) or one year (Figure 5C), indicating a severe diminution of the mesenchymal progenitor pool. Moreover, BMSC isolated from the PRBP bone were severely deficient in undergoing osteoblast differentiation when cultured in osteogenic media and monitored by the expression of alkaline phosphatase (AP) (Figure 5D). Therefore, the PRBP animals exhibited a marked deficiency in the bone marrow mesenchymal progenitor pool.

RBPjk is not critical for later stages of osteoblast lineage
To delineate potential stage-specific requirement of Notch-RBPjk signaling during osteoblast differentiation, we deleted RBPjk with either Osx-GFP::Cre [35] or 2.3ColI-Cre [36], which are believed to target progressively more mature osteoblastic cells. Western analyses confirmed that both Cre lines efficiently deleted RBPjk in the long bones (Figure 6A). However, when assessed by either X-ray radiography or μCT, neither deletion caused any significant changes in bone mass at either 8 or 21 weeks of age (Figure 6B, 6C), a finding confirmed by quantitative analyses (Table 3). Because previous studies have suggested that Notch signaling in the more mature osteoblastic cells regulated osteoclastogenesis through modulation of Rankl and Opg [23,37], we examined osteoclasts in both the Osx-GFP::Cre; RBPjk<sup>f/f</sup> (OsxRBP) and the 2.3ColI-Cre; RBPjk<sup>f/f</sup> (ColIRBP) mice. However, serum CTX assays detected no significant changes in either OsxRBP or ColIRBP mice over controls at either 8 or 21 weeks of age (Figure 6D, 6E), indicating largely normal bone resorption in these...
animals. Similarly, osteoclast number and osteoclast surface per bone surface were comparable between the mutant strains and their wild-type littermates (Figure 6D, 6E). Thus, RBPjk does not appear to play a major role in the more committed osteoblast-lineage cells.

**Hey1 and HeyL mediate Notch-RBPjk signaling in osteoblast lineage**

To assess the role of Hey1 and HeyL in bone formation, we analyzed the bones of mice wherein the two genes have been deleted. Because previous work by others revealed no major bone phenotype in the Hey1^{−/−} mice [38], we focused on the HeyL^{−/−} and the HeyL^{−/−}; Hey1^{−/−} double mutant animals, all in the C57BL6 background. As Hey1^{−/−}; HeyL^{−/−} mice died prematurely due to heart defects [39], we analyzed the bones of the viable HeyL^{−/−}; Hey1^{+/−} animals. μCT analyses showed that the HeyL^{−/−} and the HeyL^{−/−}; Hey1^{+/−} mice possessed progressively more trabecular bone than their wild-type littermates at 8 weeks of age (Figure 7A). In particular, the femoral trabecular bone mass was increased by 80% and 150% over the control in the HeyL^{−/−} and the HeyL^{−/−}; Hey1^{+/−} animals, respectively (Table 4). Moreover, like the PRBP bones, the HeyL^{−/−}; Hey1^{+/−} samples exhibited a significant increase in trabecular number and thickness with a corresponding decrease in trabeculae spacing. At the cellular level, the HeyL^{−/−}; Hey1^{+/−} bones exhibited more cuboidal osteoblasts than the wild type whereas their number of osteoclasts appeared to be normal (Figure 7B, 7C). Thus, Hey1 and HeyL, like Notch and RBPjk, negatively regulate osteoblast numbers.

**NFATc1 functions downstream of Notch-RBPjk-Hey signaling**

We next investigated the mechanism through which Notch-RBPjk-Hey signaling regulates osteoblast differentiation. In a separate effort to identify Hey1 and HeyL target genes, we performed genome-wide ChIP-seq (Chromatin immunoprecipitation followed by high-throughput sequencing) experiments by expressing Flag-tagged Hey1 or HeyL in HEK293 cells. We identified strong binding for both proteins around the P1 promoter of NFATc1 (Figure 8A and data not shown). Importantly, Hey1 was also found to bind to the NFATc1 P1 promoter region in ST2 cells, a mouse bone marrow stromal cell line that can be induced to differentiate into osteoblasts (Figure 8B); the binding is consistent with the presence of a predicted Hey1 binding site “CGCCGCG” within the region. In contrast, no binding was detected for the alternative P2 promoter (Figure 8B). We next focused on the functional relevance of Hey1 binding. Full-length Hey1, but not a form missing the HLH domain, suppressed the activity of the NFATc1 P1 promoter in transient transfection assays in both HEK293T and ST2 cells (Figure 8C). Because NFATc1 was previously shown to increase osteoblast numbers [33], we explored the potential involvement of NFATc1 in Notch-RBPjk signaling in bone. Real-time PCR revealed that NFATc1 mRNA was increased by 200% in the PRBP tibia over the control (Figure 8D). Western analyses identified a 70 kD isoform of NFATc1 greatly induced in the PRBP bones, whereas a 77 kD form was less affected (Figure 8E). To gain insight on the induced isoform, we employed semi-quantitative RT-PCR to identify the specific NFATc1 mRNA variant(s) increased in the PRBP bones. The NFATc1 mRNA variants are known to differ both at the 5′ end containing either exon1 or 2, and at the 3′ end that either terminates with exon 9b, or contains exon 9a through exon 11. By using primer pairs spanning exons 1 and 3, 2 and 3, 8 and 9b or 8 and 11, we observed a marked increase of exon 1 in the PRBP samples, whereas exon 2 was unchanged (Figure 8F). Moreover, exon 9b was enriched in PRBP over wild type, whereas exon 11
was not detectable in either genotype (Figure 8F, and data not shown). Thus, an NFATc1 mRNA variant transcribed from the P1 promoter and containing exons 1 and 9b was specifically induced in the PRBP bones.

The finding above raises the possibility that the increase in NFATc1 might contribute to the high bone mass in the PRBP mice, and further that inhibition of NFATc1 activity may be able to alleviate the phenotype. To test this hypothesis, we injected littermate PRBP animals daily with either FK506, a potent inhibitor of NFAT signaling, or vehicle, for one month starting at one month of age. As expected, the vehicle treatment did not alter the high bone mass phenotype of the PRBP animals. However, FK506 markedly reduced bone mass in the PRBP mice, especially in the femur (Figure 8G and 8H, Table 5). This reversal of the high bone mass occurred in the face of decreased bone resorption in the FK506-treated animals, as indicated by a significantly lower serum CTX level (Figure 8I), presumably due to the known role of NFAT in osteoclastogenesis [31]. The suppression of bone resorption may explain the observation that FK506 did not consistently correct the high bone mass in the tibia (data not shown). However, in one case where the serum CTX level was less affected by FK506, both the tibia and the femur were corrected (Figure S1). As controls, the wild-type littermates were subjected to the same inhibitor or vehicle treatment. Similar to a previous report [32], the trabecular bone mass was reduced in the wild-type animals by FK506, but the extent of reduction was modest compared to that seen in the PRBP mice (Figure S2). Overall, the results showed that NFAT inhibition could override the effect of RBPjk deletion on bone mass. Furthermore, because Hey1 directly inhibits NFATc1 expression, Notch-RBPjk-Hey signaling appears to inhibit bone formation in part by down-regulating NFATc1.

**Discussion**

The present study establishes canonical Notch signaling as a critical mechanism for maintaining bone homeostasis under normal physiological conditions. In this capacity, Notch appears to function as a gatekeeper to ensure that a proper number of
osteoblasts are produced during differentiation. Because removal of Notch signaling from the Osx-positive stage onward did not have an obvious effect, we propose that Notch mainly controls the transition from Runx2- to Osx-positive cells. Mechanistically, Notch signals through RBPjk to induce transcription of Hey1 and HeyL, which in turn inhibit osteoblast differentiation by suppressing both Runx2 activity [21] and NFATc1 expression (this study) (Figure 8J).

The current study not only demonstrates the stage- and receptor-specificity of Notch signaling during osteoblast differentiation, but also sheds light on the intracellular mechanism mediating Notch function. Although RBPjk was previously shown to mediate the effect of NICD overexpression on both chondrogenesis and preosteoblast proliferation [24,40], this study establishes for the first time the importance of RBPjk in physiological Notch signaling within the osteoblast lineage. Moreover, the present study uncovers a direct regulation of NFATc1 expression by Notch signaling.

The relationship between Notch and NFAT signaling warrants further investigation. The direct suppression of NFATc1 promoter by Hey1, and the dominant effect of FK506 over RBPjk removal support the model wherein NFAT functions downstream of and opposite to Notch signaling in regulating bone formation. However, we cannot rule out that FK506 may have NFAT-

### Table 3. µCT analyses of OsxRBP and ColIRBP at 8 and 21 weeks of age.

| Age   | Genotype | BV/TV | Ratio over WT | p value | Tb.N* | Ratio over WT | p value | Tb.Th* | Ratio over WT | p value | Tb.Sp* | Ratio over WT | p value |
|-------|----------|-------|---------------|---------|-------|---------------|---------|-------|---------------|---------|-------|---------------|---------|
|       |          | % (± s.d.) |             |         | 1/mm (± s.d.) |             |         | 1/mm (± s.d.) |             |         | mm (± s.d.) |         |
| 8 weeks | OsxRBP   | 5.150 ± 2.401 | 0.7 | 0.492 | 2.710 ± 0.492 | 1.4 | 0.083 | 0.002 ± 0.004 | 1.0 | 0.936 | 0.374 ± 0.077 | 0.7 | 0.082 |
|        | WT       | 7.045 ± 4.587 | | | 1.887 ± 0.377 | | | 0.051 ± 0.002 | | | 0.561 ± 0.116 | |
| 21 weeks | OsxRBP  | 7.513 ± 0.792 | 0.8 | 0.400 | 1.904 ± 0.804 | 1.2 | 0.464 | 0.060 ± 0.005 | 0.8 | 0.069 | 0.582 ± 0.211 | 0.8 | 0.262 |
|        | WT       | 8.923 ± 2.480 | | | 1.530 ± 0.167 | | | 0.073 ± 0.007 | | | 0.701 ± 0.086 | |
| 8 weeks | ColIRBP | 6.003 ± 1.908 | 1.2 | 0.724 | 2.230 ± 0.556 | 1.1 | 0.771 | 0.056 ± 0.008 | 1.1 | 0.406 | 0.451 ± 0.096 | 0.8 | 0.550 |
|        | WT       | 5.187 ± 3.216 | | | 2.135 ± 0.865 | | | 0.051 ± 0.003 | | | 0.532 ± 0.194 | |
| 21 weeks | ColIRBP | 8.025 ± 1.024 | 0.8 | 0.394 | 1.700 ± 0.063 | 1.0 | 0.693 | 0.069 ± 0.002 | 0.9 | 0.172 | 0.609 ± 0.024 | 1.0 | 0.706 |
|        | WT       | 9.533 ± 0.794 | | | 1.635 ± 0.273 | | | 0.076 ± 0.006 | | | 0.630 ± 0.198 | |

BV: bone volume; TV: total volume; Tb.N*: trabeculae number; Tb.Th*: trabeculae thickness; Tb.Sp*: trabeculae spacing; data derived from 100 of 16-µm slices immediately below growth plate. All analyses performed with sex-matched littermates (3 females for ColIRBP at either 8 or 21 weeks, 2 males and 2 females for OsxRBP at 8 weeks, 1 male and 2 females for OsxRBP at 21 weeks).

doi:10.1371/journal.pgen.1002577.t003

### Figure 7. Bone phenotypes of Hey1 and HeyL mutant mice at 8 weeks of age. (A) µCT 3-D reconstruction of metaphyseal trabecular bone of the femur from WT, HeyL−/−, and HeyL−/−; Hey1+/−. (B) Number of osteoblasts per trabecular bone area on sections (No. OB/mm²). (C) Number of osteoclasts normalized to trabecular bone perimeter (No. OC/mm). Bar graphs show mean ± s. d., ** p < 0.01, n = 4.

doi:10.1371/journal.pgen.1002577.g007
independent functions, or that the systemically-delivered FK506 acted on other cell types to affect bone mass indirectly. Our finding that Hey1 binds to and suppresses the NFATc1 promoter is consistent with a recent report that Notch inhibited NFATc1 transcription in ST2 and primary osteoblasts [41]. However, NFATc1 is unlikely to be the sole effector, as simultaneous removal of NFATc1 and RBPjk with Prx1-Cre did not rescue the high bone mass phenotype caused by RBPjk deletion (data not shown). NFATc2 may play a redundant role as it was previously shown to stimulate osteoblast differentiation [32]. Indeed, Western blotting showed that several isoforms of NFATc2 were markedly increased in the PRBP bones over the control (Figure S3). The mechanism for this upregulation however, is currently unknown. Future experiments with simultaneous deletion of NFATc1 and

Table 4. μCT analyses of HeyL−/−; Hey1−/− and HeyL−/− at 8 weeks of age.

| Genotype          | BV/TV  | Tb. N* | Tb.Th* | Tb.Sp* |
|-------------------|--------|--------|--------|--------|
|                   | % (±s.d.) | 1/mm | % (±s.d.) | 1/mm | % (±s.d.) | 1/mm |
| HeyL−/−           | 17.027 ± 2.818 | 1.8  | 2.410 ± 0.321 | 1.1  | 0.101 ± 0.003 | 1.2  |
| HeyL−/−; Hey1−/− | 23.254 ± 4.123 | 2.5  | 3.295 ± 0.480 | 1.5  | 0.107 ± 0.009 | 1.3  |
| WT                | 9.320 ± 1.675  | 2.247 ± 0.477 | 0.081 ± 0.018 | 0.483 ± 0.109 |

BV: bone volume; TV: total volume; Tb.N*: trabeculae number; Tb.Th*: trabeculae thickness; Tb.Sp*: trabeculae spacing. Data derived from 100 of 16-mm slices immediately below growth plate, n = 4 for each group (all females in C57BL6 background).

doi:10.1371/journal.pgen.1002577.t004

Figure 8. Relationship between Notch-RBPjk and NFAT in bone. (A) ChIP-seq data showing Flag-Hey1 binding at NFATc1 P1 promoter region in HEK293T cells. (B) ChIP showing Flag-Hey1 bound to P1 but not P2 promoter of NFATc1 in ST2 cells. (C) NFATc1 P1 promoter luciferase reporter assays in ST2 and HEK293T cells. (D) NFATc1 real-time PCR with total RNA from tibiae of 8-week-old mice. (E) Western blot analysis of NFATc1 in protein extracts from tibiae and femora at 8 weeks. (F) Exon-specific RT-PCR of NFATc1 mRNA variants in bone RNA from 8-week-old mice. W: wild type mice; M: PRBP mice; GDH: glyceraldehyde 3-phosphate dehydrogenase. (G) X-ray radiographs of femora from PRBP mice treated with vehicle (Veh.) or FK506 (FK). (H) μCT 3-D reconstruction of the femur metaphyseal trabecular region. (I) Serum CTX assays. (J) A model for Notch signaling in regulating osteoblast differentiation. ↓: stimulation; ⊥: negative regulation. Bar graphs show mean ± s. d., * p<0.05, ** p<0.01, n = 3.

doi:10.1371/journal.pgen.1002577.g008
NFATc2 will test the hypothesis that the two proteins redundantly mediate Notch function in bone.

Notch-RBPjk removal from the early limb mesenchyme led to a severe deficit in type I CFU-F in the postnatal bone marrow. This phenotype could reflect either a direct requirement of Notch signaling in the CFU-F cells, or a secondary effect due to changes in osteoblast differentiation. To distinguish these possibilities, we performed lineage-tracing experiments with the Rosa26 reporter mouse, and observed that the type I CFU-F cells were not targeted by Prx1-Cre although some stromal cells in the same culture were (data not shown). In addition, experiments with a transgenic mouse (TNR) that reports Notch-RBPjk signaling [42] revealed that some stromal cells but not the type I CFU-F cells exhibited canonical Notch signaling in vitro (data not shown). Thus, diminution of bone marrow mesenchymal progenitors, as reflected by CFU-F assays in vitro, was likely to be secondary to changes in osteoblast differentiation. In this scenario, assuming mesenchymal progenitors normally exist in equilibrium with Runx2-positive osteogenic precursors, we envision that unchecked differentiation of the latter due to Notch deficiency may lead to exodus of cells from the mesenchymal progenitor pool. Alternatively, the altered bone marrow environment due to the excessive bone mass in Notch-deficient mice may be unfavorable for either establishing or maintaining a normal mesenchymal progenitor pool.

A mechanistic understanding of the dominance of Notch2 over Notch1 awaits further studies. A similar dominance of Notch2 over 1 was observed during nephron formation in the mouse embryo [43,44], whereas a dominance of Notch1 over 2 was reported in the skin [45,46] as well as in osteoclasts [37]. The mechanism underlying the differential roles among Notch paralogs is currently unclear, but it could reflect differences in either expression levels or ligand-binding affinities among the different receptors within a given cell type. This model predicts that Notch2 is normally preferably activated in the osteogenic progenitors. Alternatively, Notch1 and2 may be similarly activated but Notch2-NICD is more potent than Notch1-NICD in suppressing osteoblast differentiation. However, Notch 1 deficiency was sufficient to cause ectopic ossification in human aortic valves [25]. Thus, the relative contribution of Notch1 versus 2 in suppressing the osteogenic program appears to be context dependent.

The effect of Notch signaling in osteoblast-lineage cells on osteoclast differentiation is likely to be complex. Although TRAP-positive osteoclasts were more abundant than normal within the metaphyseal trabecular region of the PRBP bones, the total bone resorption activity was relatively normal at 8 weeks of age. However, by 26 weeks bone resorption was more robust in the PRBP mice than the littermate control, and likely contributed to the rapid bone loss seen at this age. The mechanism for the age-dependent bone resorption phenotype is not understood at present, but likely involves additional factors beyond Notch deficiency in the osteoblast lineage. In addition, unlike the PRBP mice, the PN1, PN2, OsxRBP and ColIRBP mice did not display an obvious bone resorption phenotype at either 8 or 21 weeks, even though certain changes in M-CSF, Rankl and Opg were observed in these animals (Figure S4). The lack of bone resorption phenotype in the ColIRBP mice appears to be at odds with the previous report that deletion of presenilin 1 and 2 by 2.3Col1-Cre caused an increase in bone resorption at six months, although not at three months of age [23]. Besides trivial explanations such as slight age differences or genetic background variations between the two studies, the discrepancy could indicate that the previously observed effect was independent of RBPjk. In summary, the predominant function of physiologic canonical Notch signaling in the osteoblast lineage is suppression of osteoblastogenesis from the precursors. Thus, potential pharma-

| Table 5. pCT analyses of FK-506-injected PRBP mice. |
|---------------------------------|
| BV/TV  | Ratio over vehicle | p value | BV: bone volume; TV: total volume; Tb. N*: trabeculae number; Tb. Th*: trabeculae thickness; Tb. Sp*: trabeculae spacing. |
| FK506 | 4.078 6 | 0.14 0.003 0.42 0.167 | 1.073 0.63 0.207 |
| Vehicle | 30.138 6 | 7.444 3.594 1.540 0.124 |

| Tb. Th*  | Ratio over vehicle | p value |
|---------|------------------|---------|
| FK506 | 3.585 0.14 0.003 | 2.245 1.073 |
| Vehicle | 3.645 1.480 | 3.645 1.440 |

| Tb. Sp*  | Ratio over vehicle | p value |
|---------|------------------|---------|
| FK506 | 0.167 1.45 0.182 | 0.051 0.42 0.003 |
| Vehicle | 0.124 | 0.029 0.346 |

| p value |
|---------|
| 0.011 |

| BV: bone volume; TV: total volume; Tb. N*: trabeculae number; Tb. Th*: trabeculae thickness; Tb. Sp*: trabeculae spacing. Data derived from 100 of 16-μm slices immediately below growth plate, n = 4 for each group, all analyses done with sex-matched littermates (3 females and 1 male). |
ceutical inhibition of this pathway in osteogenic progenitors may be beneficial for bone formation.

**Materials and Methods**

**Mouse strains**

The Nf1f/f [47], Nf2f/f [48], Prx1-Cre [34], Hey1f/f [39], 2.3Col1-Cre [36], Osteo-GFP::Cre [35], Prxl-Cre [34], Hey2f/f [50], HeyLf/f- [39] and NFATc1f/f [51] mouse strains are as previously described. The Animal Studies Committee at Washington University approved all mouse procedures.

**Analyses of mice**

Radiographs of mouse skeleton were generated using a Faxitron X-ray system (Faxitron X-ray Corp) with 20-second exposure under 25 kV. Micro computed tomography (µCT 40, Scanco Medical AG) was used for three-dimensional reconstruction, and quantification of bone parameters (threshold set at 200). Serum CTX assays were conducted with mice without feeding for 6 hours with the RatLaps ELISA kit (Immunodiagnostic Systems Ltd.). H&E, TRAP and picro-sirius red staining were performed on paraffin sections, following decalcification for postnatal samples. For dynamic histomorphometry of postnatal mice, calcein (Sigma) was injected intraperitoneally at 7.5 mg/kg on days 7 and 2 prior to sacrifice, and bones were sectioned in methyl-methacrylate. Bioquant II was used for quantification in both static and dynamic bone histomorphometry. FK506 (Sigma) was dissolved in DMSO to sacrifice, and bones were sectioned in methyl-methacrylate. For dynamic histomorphometry of postnatal mice, calcein (Sigma) was injected intraperitoneally at 7.5 mg/kg on days 7 and 2 prior to sacrifice, and bones were sectioned in methyl-methacrylate. Bioquant II was used for quantification in both static and dynamic bone histomorphometry. FK506 (Sigma) was dissolved in DMSO to sacrifice, and bones were sectioned in methyl-methacrylate. Bioquant II was used for quantification in both static and dynamic bone histomorphometry.

**Cell cultures, transfections, and analyses of protein and RNA**

The CFU-F and osteoblast differentiation assays were performed as previously described [21]. Only type I CFU-Fs were scored in the present study. Transient transfections were performed as follows. ST2 were plated at 3x10⁴/well in a 24-well plate overnight, and transfected with pCS2-Hey1, pCS2-Hey1-DHLH or empty pCS2 vector (0.2 µg) [21], pNFATc1-0.8P1 (0.1 µg) [52] and pRL-Renilla (0.01 µg, Promega) for 8 h using Lipofectamine (1 µl/well). HEK293T cells were plated at 4x10⁴/well in a 12-well plate overnight, transfected with pCS2-Hey1, pCS2-Hey1-DHLH or empty pCS2 vector (0.4 µg), pNFATc1-0.8P1 (0.2 µg) and pRL-Renilla (0.02 µg) using Fugene (1.8 µl/well). The transfected ST2 or HEK293T cells were harvested at 48 hours after the beginning of transfection and subjected to dual luciferase activity assays (Promega).

Western analyses were performed with bone proteins extracted with RIPA buffer from tibiae and femora that were cut into small pieces after bone marrow cells were flushed out. The Notch 1 monoclonal antibody mN1A was as previously described [33], and the Notch 2 antibody (C651.6DbHN) was from Developmental Studies Hybridoma Bank at the University of Iowa. The antibody against RBPjk was from Cosmobio (Japan).

Real-time PCR was performed with SYBR-Green (Roche) in ABI-7500 (Applied Biosystems) using cDNA reverse-transcribed from bone total RNA, extracted with Trizol (Invitrogen) from pulverized tibia and femur after removal of the bone marrow. Sequence information for the real-time PCR primers is listed in Table S1. The exon-specific primers for NFATc1 (Table S2) were as previously described [54], but the exons were renumbered according to the current NCBI nucleotide database. Semi-quantitative RT-PCR for NFATc1 was performed at an annealing temperature of 57°C for 40 cycles. GAPDH used as loading control was amplified for 30 cycles.

**ChIP experiment**

ST2 cells were infected with lentivirus to express a doxycycline-inducible Flag-Hey1 transgene. Flag-Hey1 expression was induced with 100 ng/mL Doxycycline (Sigma D9891) for 12 hours. Chromatin and protein complexes were crosslinked for 10 minutes in 1% formaldehyde and flash frozen. The chromatin was sonicated to an average size of 200–450 bp using a Sonics Vibracell sonicator (model Vcx 500). Chromatin complexes were immunoprecipitated using an anti-Flag antibody (Sigma F1804). Immunoprecipitated DNA fragments were amplified by PCR using primers adjacent to a predicted Hey1-binding site within the P1 promoter of the mouse NFATc1 gene (5’- TCTCGTGTCTCATCAGGCAGCA - 3’ and 5’- TTGCCCTCTTTGATACCTTGGCCCA - 3’), or primers near the P2 promoter approximately 4 Kb downstream (5’- TCCGGGTTTACATAACAAAGGGG - 3’ and 5’- ACTGCAACACCGCTGAACAGGAA - 3’).

**ChIP–seq analysis**

HEK293 cells that expressed a doxycycline-regulated Flag-Hey1 or -HeyL transgene were used for ChIP-seq analysis. Cells were induced with 50 ng/ml doxycycline for 48 hours to ensure a low-level expression and Hey1- or HeyL-containing chromatin was immunoprecipitated with a Flag antibody. Cells carrying the same transgenes but grown without doxycycline were used as control. Preparation of ChIP libraries, Illumina sequencing and data analysis were performed as previously described [55].

**Supporting Information**

**Figure S1** Correction of the high-bone-mass phenotype in the tibia by FK506. (A) X-ray radiographs of the tibia. Note a notable correction of the shape of the tibia. B) Data from µCT analyses and serum CTX assays of animals in (A).

**Figure S2** Effect of FK506 on trabecular bone mass of wild type mice. Shown are µCT 3-D reconstruction images of the metaphyseal trabecular region of the tibia.

**Figure S3** Western analyses of NFATc2;2 in protein extracts from tibiae and femora of 8-week-old PRBP versus wild-type littermates.

**Figure S4** Real-time PCR of osteoclastogenic factors in bone RNA from indicated mouse strains. Values are normalized to wild type levels (designated 1). Bar graphs show mean ± s. d., *p<0.05, **p<0.01, n = 3.

**Table S1** Real-time PCR primers.

**Table S2** NFATc1 exon-specific PCR primers.

**Acknowledgments**

We thank Dr. Jenna Regan for her help in surveying potential target tissues of Prxl-Cre.

**Author Contributions**

Conceived and designed the experiments: FL. Performed the experiments: XT JC JL CMK S-YL JH CW. Analyzed the data: XT FL. Contributed reagents/materials/analysis tools: KS RK MG. Wrote the paper: XT FL.
Notch and NFAT in Bone Formation

References

1. Artavas was-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770–776.
2. Chiba S (2006) Notch signaling in stem cell systems. Semin Cells Dev Biol 24: 2457–2457.
3. D'Souza B, Meloty-Kapella L, Weinmaster G (2010) Canonical and non-canonical Notch ligands. Curr Top Dev Biol 92: 73–129.
4. Schroeter EH, Kusserow JA, Kopan R (1999) Notch-l signaling requires ligand-induced proteolytic release of intracellular domain. Nature 393: 302–306.
5. Kopan R, Gao A (2000) A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev 14: 2799–2006.
6. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 217–223.
7. Honjo T (1996) The shortest path from the surface to the nucleus: RBP-J kappa/Su(H) transcription factor. Cells 1: 1–9.
8. Ito T, Kedes L, Hamanowicz Y (2003) HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Biol 194: 237–255.
9. Martinez Arias A, Zecchin V, Brennan K (2002) CSL-independent Notch signalling: a checkpoint in cell fate decisions during development? Curr Opin Genet Dev 12: 324–333.
10. McDonald R, Warthen DM, Sanchez-Lara PA, Pai A, Kranz ID, et al. (2006) NOTCH2 mutations cause Aлагille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 79: 169–173.
11. Sanders PG, Munoz-Descalzo S, Balayes T, Wirtz-Peitz C, Hayward P, et al. (2009) Ligand-independent traffic of Notch buffers activated Armadillo in Drosophila. PLoS Biol 7: e1000169. doi:10.1371/journal.pbio.1000169.
12. Dunwoodie SL, Clements M, Sparrow DB, Sa X, Cordon RA, et al. (2002) Axial skeletal defects caused by mutation in the spondylocostal dysplasia/papugy gene DBD3 are associated with disruption of the segmentation clock within the presomitic mesoderm. Development 129: 1795–1806.
13. Shen J, Bronson RT, Chen DF, Xia W, Soller DJ, et al. (1997) Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89: 629–639.
14. Wong PC, Zheng H, Chen H, Becher M, Struminski DJ, et al. (1997) Presenilin 1 is required for Notch1 and DII expression in the paraxial mesoderm. Nature 387: 280–292.
15. Zhang X, Gridley T (1998) Defects in somite formation in hatchling fringe-deficient mice. Nature 394: 374–377.
16. Pan Y, Liu Z, Shen J, Kopan R (2005) Notch1 and 2 cooperate in limb ectoderm to receive an early Jagged2 signal regulating interdigital apoptosis. Dev Biol 286: 472–482.
17. Jiang R, Lain Y, Chapman HD, Shascher C, Norton CR, et al. (1996) Defects in limb, craniofacial, and dynamic development in Jagged2 mutant mice. Genes Dev 10: 1046–1057.
18. Bulman MP, Kusumi K, Trayling TM, McKennon C, Garrett C, et al. (2000) Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis. Nature Genet 24: 438–441.
19. Li L, Kranz ID, Deng Y, Genin A, Banta AB, et al. (1997) Algill disease is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 16: 243–251.
20. Oda T, Elkhodou AG, Pike BL, Okajima K, Kranz ID, et al. (1997) Mutations in the human Jagged1 gene are responsible for Aлагille syndrome. Nature Genet 16: 215–218.
21. Hilson MJ, Tu X, Wu X, Bai S, Zhao H, et al. (2008) Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 14: 306–314.
22. Zanotti S, Smerdel-Ramoya A, Canalis E (2010) Reciprocal regulation of notch signaling in osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem 285: 6509–6518.
23. Sale R, Külisch M, Vokevic M, Zamurovic N, Kramer I, et al. (2010) Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and chondrocyte hypertrophy in bone. Gene 46: 680–694.
24. Fischer A, Seridi C, Wagner TL, Leng E, Jakob PM, et al. (2007) Combined loss of Hey1 and Hey2 causes congenital heart defects because of impaired epithelial to mesenchymal transition. Circ Res 100: 856–863.
25. Dong Y, Jesse AM, Kohn A, Gunnell LM, Honjo T, et al. (2010) RBP-Kappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and the differentiation during skeletal development. Development 137: 1461–1471.
26. Zanotti S, Smerdel-Ramoya A, Canalis E (2010) Reciprocal regulation of notch and nuclear factor of activated T-cells (NFATc1) transactivation in osteoblasts. J Biol Chem.
27. Durieux M, Yoon K, Dinh L, Tokunaga A, Gaiwana N (2007) Differential Notch signaling distinguishes neural stem cells from intermediate progenitors. Nature 449: 351–355.
28. Cheng HT, Kim M, Valerius MT, Surendran K, Schuster-Gossler K, et al. (2007) Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development 134: 801–811.
29. Surendran K, Boyle S, Barak H, Kim M, Stommberski C, et al. (2009) The contribution of Notch1 to nephron segmentation in the developing kidney is revealed in a sensitized Notch2 background and can be augmented by reducing Mint dosage. Dev Biol 337: 386–393.
30. Rangananj A, Tabera C, Okamura Y, Nicolas M, Mammucari C, et al. (2001) Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. Embo J 20: 3437–3446.
31. Deneshe S, Turkoz A, Kopan R (2009) Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 16: 55–66.
32. Pan Y, Liu MH, Tian X, Cheng HT, Gridley T, et al. (2004) gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev Cell 7: 731–743.
33. Mcgriff T, Louzir J, Gridley T (2006) Generation of new Notch2 mutant alleles. Genesis 44: 29–33.
34. Han H, Tanigaki K, Kuroda K, Yoshimoto M, et al. (2002) Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Immol 14: 637–645.
35. Fischer A, Schumacher N, Maier M, Sendmmer M, Gosler M (2004) The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genesis 38: 901–911.
36. Aliprantis AO, Uckl Y, Sulyanto R, Park A, Sigrist KS, et al. (2008) Notch1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118: 3737–3739.
37. Chappuis S, Jankovec E, Tysyn D, Akamahov A, Moroz D, et al. (2002) Autoregulation of NFAT1/A expression facilitates effector T cells to escape from rapid apoptosis. Immnunol 16: 801–895.
38. Huppert SS, Le A, Schroeter EH, Mumm JS, Saxenw MT, et al. (2000) Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1. Nature 405: 966–970.
39. Vihma H, Pruunsild P, Timmusk T (2008) Alternative splicing and expression of human and mouse NFAT genes. Genomics 92: 279–291.
40. Weis CL, Wu Q, Vega VB, Chin KP, Ng P, et al. (2006) A global map of p33 transcription-factor binding sites in the human genome. Cell 124: 207–219.